Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
about
Opioids for agitation in dementiaOpioids for agitation in dementiaQuetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialAssessment and management of behavioral and psychological symptoms of dementiaRecommendations for the management of behavioral and psychological symptoms of dementia.Bipolar disorder in old ageAssessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature.Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence.Packages of care for dementia in low- and middle-income countries.Behavioral disturbances of dementia.Managing common behavioral problems in dementia. How to improve quality of life for patients and families.Strategies for optimizing antiepileptic drug therapy in elderly people.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?Gabapentin for treatment of behavioral and psychological symptoms of dementia.A systematic mapping review of randomized controlled trials (RCTs) in care homesPharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.Approach to managing behavioural disturbances in dementia.Development of frontotemporal dementia in a case of bipolar affective disorder: is there a link?The use of newer anticonvulsants in neuropsychiatric disorders.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Behavior problems in demented nursing home residents: a multifaceted approach to assessment and management.Valproate.Medical management of advanced dementia.Frequency of behavioral symptoms characterizes agitation in Alzheimer's disease.Treating Psychotic Symptoms in Elderly Patients.Current status of the utilization of antiepileptic treatments in mood, anxiety and aggression: drugs and devices.Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based studyThe management of inappropriate vocalisation in dementia: a hierarchical approach.Pharmacological management of behavioural and psychological disturbance in dementia.Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies.Neuroleptic drugs in dementia: benefits and harm.Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.Psychiatric and behavioral manifestations of vascular dementia.ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.Alzheimer's disease and mild cognitive impairmentPharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.
P2860
Q24187950-FE48EB6A-1256-418D-904D-640B169D95FFQ24201556-5E6A6990-ACD6-4A62-AC91-68D041689B61Q24555726-EF82E7A1-347C-4524-A0E0-D4C4314AD5AAQ28088782-054A3BF9-097D-4F27-BB2A-5F6AC8246C25Q30327961-8C46E94F-DD65-462F-9C28-84C818205741Q30494764-B712AC0F-86BB-4F9D-B275-9072268C13A4Q30540486-ECD51003-EFFE-4C2C-8C55-13E6CB546BB4Q33323206-F5C9B05F-33D9-42BC-8150-E9012F80BC7BQ33514859-21222C23-14C6-4992-8670-36C979D37576Q33609591-84AF3C2E-A26F-4739-A1DF-FD768BA1BE99Q33772818-6BD22A37-8E43-4D44-80B5-94716411AB48Q34118987-3113DAA6-9217-4A06-AB31-4367857C7F27Q34146983-C9DEFB74-9B64-4527-818E-F5A454E72577Q34219064-4D642319-B782-4D43-9191-CD42DA930214Q34316513-58F88D9B-6407-411E-AEFF-9C203865BA85Q34452896-E6D7D055-7A02-4B45-BAE5-1DEC532D7C79Q34683770-2F02B439-99FC-4E8F-ABEC-744A7E4E9D32Q34707367-8EC7A58B-18C0-476A-B211-4253552C9740Q34856249-CF1FCA3B-C8E1-4792-9ABA-AC3A945CDF79Q34987695-79D23B72-3659-4886-8671-47306A104135Q35036002-39CF74A9-2FD0-44D2-AB4E-F0B3687D7A0FQ35142736-CDC929C7-F163-4D13-84E3-E84ED7A4BC0EQ35151992-D8FBF8E3-2235-4860-82E7-2527340E872AQ35215617-7E86B254-9CA7-41C7-9395-3B48F3A90BE4Q35666369-B9C1DF2F-C7BD-480F-89AA-B05329C834E3Q35757913-A2A28C43-0D63-4155-BD60-3D7A10B49C64Q35765716-37CE3233-DF9C-4503-908C-3E6B40AEE74DQ35884948-F81A1FC4-108A-449B-8258-340DDB432E7FQ35953332-EC2437F3-BE22-49A5-AAA0-792704C8B7F8Q36325800-6DA0C8C6-3893-47AE-88C4-D6040834B709Q36359134-6CB812B3-5D33-4C38-B8E2-EF868C2B7E6AQ36399561-1D4FC555-6F8F-4059-A648-8D3BF4922F61Q36484553-CFCADA05-2AFF-4759-84B8-CF65F3CB720DQ36729609-B54909EA-3733-49C4-925B-F0D4BA032D84Q36742405-F04548C8-C256-4732-B1A3-B09EEDD2E78BQ36812783-40B98ED6-8C3C-4959-AB32-A66E2AFEE720Q36885358-ADC83945-1B57-4046-9FC4-A474065E2687Q36894385-5480D778-15CB-4805-96AD-135D27D5AD65Q36948428-DD29F9C1-8073-42C8-9C17-2AB1F71EE693Q37004363-2F1444EF-F01B-45CD-A341-DB27495AD9A0
P2860
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@en
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@nl
type
label
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@en
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@nl
prefLabel
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@en
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@nl
P2093
P356
P1476
Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
@en
P2093
Jakimovich L
Podgorski CA
P356
10.1176/AJP.155.1.54
P407
P577
1998-01-01T00:00:00Z